Truist analyst Richard Newitter raised the firm’s price target on Inspire Medical to $330 from $310 and keeps a Buy rating on the shares. The company’s Q4 marked a "solid beat" and its outlook likely leaves room for upside, the analyst tells investors in a research note, also noting that the stock remains the firm’s top FY23 pick. The firm adds that Inspire’s monthly its total addressable market.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INSP:
- Inspire Medical price target raised to $305 from $300 at Piper Sandler
- Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance
- Inspire Medical reports Q4 EPS 10c, consensus (57c)
- Inspire Medical price target raised to $310 from $308 at Truist
- CVRx initiated with a Buy at Lake Street
